Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)

Summary

This is a pilot study to evaluate feasibility, safety, and preliminary evidence of efficacy for intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains (referred to as "RNA CART-cMET") in patients with advanced melanoma or breast carcinoma.

Timeline

Start

2016-12-21

Primary completion

2020-03-27

Completion

2020-03-27

Outcome

Outcome not reported

Stopped (Business): “Halt in funding”

Publications

• Shah PD, Huang AC, Xu X, Orlowski R, Amaravadi RK, Schuchter LM, Zhang P, Tchou J, Matlawski T, Cervini A, Shea J, Gilmore J, Lledo L, Dengel K, Marshall A, Wherry EJ, Linette GP, Brennan A, Gonzalez V, Kulikovskaya I, Lacey SF, Plesa G, June CH, Vonderheide RH, Mitchell TC. Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. Cancer Res Commun. 2023 May 9;3(5):821-829. doi: 10.1158/2767-9764.CRC-22-0486. eCollection 2023 May.

Drugs

Indications